VENLAFAXIN MYLAN 150 MG CPS PRO 30

What is the maximum co-payment for VENLAFAXIN MYLAN?

If the insurance company contributes, the maximum co-payment is 136,19 Kč. The maximum pharmacy price is 300,17 Kč. A pharmacy may provide the medicine for a lower price, but not for a higher price.

Does the medicine have reimbursement from public health insurance?

Yes, zkontrolujte ale specializaci předepisujího lékaře níže.

Does VENLAFAXIN MYLAN have a counted co-payment set?

Yes, the medicine has a counted co-payment of 50,00 Kč. Learn more about the protective limit here.

How much does the insurance company pay for one dispensed reimbursed pack?

163,98 Kč.

Does the insurance company pay a higher amount in some cases?

No, the medicine has no increased reimbursement.

Does the medicine have an indication restriction?

The medicine has no indication restriction. Its reimbursement is not conditional on a specific diagnosis or clinical condition.

Is it available without a medical prescription?

No, the medicine cannot be obtained without a prescription.

Which medical specialist may prescribe VENLAFAXIN MYLAN?

psychiatry, child and adolescent psychiatry, geriatric psychiatry
sexology
neurology, pediatric neurology

What is the composition of VENLAFAXIN MYLAN?

Venlafaxin-hydrochlorid (169,7 mg), venlafaxin (150 mg), neznámá látka s kódem 14508, neznámá látka s kódem 3786, natrium-lauryl-sulfát, magnesium-stearát, kopolymer ethyl-akrylátu a methyl-methakrylátu 7:3, oxid titaničitý, sodná sůl erythrosinu, indigokarmín, želatina (118 mg), černý oxid železitý, šelak. More information about the composition can be found in the SPC, section 6.1.

Where can I find information about correct use of the medicine?

Documents could not be found

Which medicines are similar to VENLAFAXIN MYLAN?

The medicine belongs to ATC group N06AX16 – VENLAFAXIN. Medicines with the same active substance can be found here.

Who manufactures VENLAFAXIN MYLAN?

VIATRIS LIMITED, Dublin (IRL)

Is the medicine in shortage?

The latest report from the manufacturer is from 29. 9. 2025. Production was terminated with effect from 3. 10. 2025. The manufacturer lists medicines with the following code as a potential substitute: